The Ubrelvy (ubrogepant tablets) from Allergan have been approved by the Food and Drug Administration (FDA) as an oral treatment for those who suffer with acute migraines with or without auras in adults. The treatment consists of recommended 50mg or 100mg doses that can be taken orally with a second dose that can be taken after two hours, if needed. The product comes as the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist, which will come as welcome news to those who suffer with acute migraines.
Ubrelvy is expected to launch in the first quarter of 2020 in specialized unit-dose packets that contain one tablet to streamline the ease of administration for patients.
Fast-Acting Migraine Treatments
Ubrelvy Has Been Approved by the FDA for Acute Migraine Treatment
Trend Themes
1. Oral CGRP Receptor Antagonist Treatments - The development of more oral calcitonin gene-related peptide (CGRP) receptor antagonist treatments presents opportunities for faster-acting and more convenient migraine treatments.
2. Specialized Unit-dose Packaging - The utilization of specialized unit-dose packaging for migraine treatments like Ubrelvy presents opportunities for more streamlined and easy administration for patients.
3. Personalized Migraine Treatments - The development of migraine treatments like Ubrelvy tailored to individual needs and responses presents opportunities for more effective and efficient personalized treatments.
Industry Implications
1. Pharmaceuticals - The pharmaceutical industry can leverage the development of faster-acting and more convenient migraine treatments like Ubrelvy to tap into a growing market demand for more effective and efficient relief.
2. Healthcare - The healthcare industry can explore the potential of specialized unit-dose packaging for migraine treatments like Ubrelvy to improve patient outcomes and experiences.
3. Technology - The development of personalized migraine treatments requires the utilization of cutting-edge technology and provides opportunities for innovation in the technology industry.